title: Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse.
abstract: We developed a PCR-based method to monitor clonogenic IgH VDJ rearrangement as a possible predictor of relapse in patients with acute B-ALL after allogeneic bone marrow transplantation (BMT). We studied 23 patients at diagnosis, before and after BMT. At the time of BMT, 13 patients were in first complete remission, eight in second complete remission and two in relapse. Four patients were PCR negative before BMT and remained PCR negative also after BMT (-/- pattern). They are still in remission after a median follow-up of 41 months. Nineteen patients were MRD-positive before BMT: three were PCR negative at first determination after BMT (+/- pattern) and maintain remission. Sixteen patients were PCR-positive at first determination after BMT (+/+ pattern): five became PCR negative (+/+/- pattern) (four with chronic graft-versus-host disease (GVHD) and two after donor lymphocyte infusions (DLI)). Nine patients remained PCR-positive (+/+/+ pattern) (four remain in remission, and six relapsed); two patients died before transplant. In conclusion, PCR negative patients before BMT remained negative post-BMT; many pre-BMT positive patients had initial MRD positivity after BMT: 37% of them achieved a molecular remission with cGVHD or DLI.
authors.affiliation: Department of Internal Medicine (DIMI), Università degli Studi di Genova, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Miglino
authors.forename: G
authors.initials: G
authors.lastname: Berisso
authors.forename: R
authors.initials: R
authors.lastname: Grasso
authors.forename: L
authors.initials: L
authors.lastname: Canepa
authors.forename: M
authors.initials: M
authors.lastname: Clavio
authors.forename: I
authors.initials: I
authors.lastname: Pierri
authors.forename: D
authors.initials: D
authors.lastname: Pietrasanta
authors.forename: S
authors.initials: S
authors.lastname: Gatto
authors.forename: R
authors.initials: R
authors.lastname: Varaldo
authors.forename: F
authors.initials: F
authors.lastname: Ballerini
authors.forename: S
authors.initials: S
authors.lastname: Verdiani
authors.forename: L
authors.initials: L
authors.lastname: Casarino
authors.forename: F
authors.initials: F
authors.lastname: DeStefano
authors.forename: M
authors.initials: M
authors.lastname: Sessarego
authors.forename: A
authors.initials: A
authors.lastname: Dominietto
authors.forename: A M
authors.initials: AM
authors.lastname: Raiola
authors.forename: S
authors.initials: S
authors.lastname: Bregante
authors.forename: C
authors.initials: C
authors.lastname: di Grazia
authors.forename: M
authors.initials: M
authors.lastname: Gobbi
authors.forename: A
authors.initials: A
authors.lastname: Bacigalupo
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D005260:Female; D005500:Follow-Up Studies; D015321:Gene Rearrangement; D005803:Genes, Immunoglobulin; D006801:Humans; D017710:Lymphocyte Transfusion; D008297:Male; D018365:Neoplasm, Residual; D016133:Polymerase Chain Reaction; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D012008:Recurrence; D014184:Transplantation, Homologous; D016896:Treatment Outcome